FIELD: medicine.
SUBSTANCE: present invention relates to a method for the treatment, control, deceleration or prevention of a condition that can be treated, controlled, decelerated or prevented, using PTH. In this case, a pharmaceutical composition contains at least one PTH compound of controlled release or its pharmaceutically acceptable salt, hydrate or solvate for use for the treatment, control, deceleration or prevention of a condition that can be treated, controlled, decelerated or prevented, using PTH. The specified pharmaceutical composition is administered of no more than once every 24 hours, with a dose of the PTH compound of controlled release that corresponds to no more than 70% molar equivalent PTH 1-84 dose administered every 24 hours, necessary for maintenance of a calcium level within normal levels for the specified 24 hour period in humans.
EFFECT: obtaining a PTH compound of controlled release.
9 cl, 20 ex
| Title | Year | Author | Number |
|---|---|---|---|
| LIQUID PHARMACEUTICAL FORMULATIONS OF PTH CONJUGATES | 2020 |
|
RU2817015C2 |
| PTH COMPOUNDS WITH LOW PEAK-TO-MINIMUM RATIOS | 2017 |
|
RU2766959C2 |
| ANTIBODIES AGAINST CXCR2 AND THEIR USE | 2019 |
|
RU2807067C2 |
| MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE HAVING SUBSTITUTE FUNCTIONAL ACTIVITY OF BLOOD COAGULATING FACTOR VIII CO-FACTOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SPECIFIED MOLECULE AS ACTIVE INGREDIENT | 2018 |
|
RU2812909C2 |
| AMATOXIN ANTIBODY-DRUG CONJUGATES AND USE THEREOF | 2020 |
|
RU2826004C2 |
| CONJUGATES OF BINDER AND ACTIVE SUBSTANCE (ADC) HAVING ENZYMATICALLY CLEAVABLE GROUPS | 2017 |
|
RU2761390C2 |
| ANTIBODIES TO MYOSTATIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2778945C2 |
| ANTIBODIES TO MYOSTATIN, POLYPEPTIDES CONTAINING FC REGION VARIANTS AND METHODS OF THEIR USE | 2015 |
|
RU2799522C2 |
| ATRIAL NATRIURETIC PEPTIDE GRAFTED ANTIBODIES | 2019 |
|
RU2822433C2 |
| COMBINED FORMULATIONS OF ANTI-LAG3 ANTIBODY AND ANTI-PD-1 ANTIBODY | 2019 |
|
RU2822192C2 |
